Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3CNS 3Thoracic 2Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Lymphoma 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Lymphoma, Non-Hodgkin 105Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84Lymphoma, Follicular 68Hodgkin Disease 54Burkitt Lymphoma 52Multiple Myeloma 51Lymphoma, B-Cell 51Recurrence 46Lymphoma, Mantle-Cell 46Leukemia, Myeloid, Acute 44Leukemia 37Neoplasms 35Hematologic Neoplasms 32Myelodysplastic Syndromes 29Lymphoma, B-Cell, Marginal Zone 26Waldenstrom Macroglobulinemia 22Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, T-Cell 18Lymphoma, T-Cell, Peripheral 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Leukemia, B-Cell 16Lymphoma, Large-Cell, Anaplastic 15Sarcoma 13Leukemia, Biphenotypic, Acute 13Mycosis Fungoides 11Melanoma 10Lymphoma, T-Cell, Cutaneous 10

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × Lymphoid × 30 days × Clear all
NCT05092451 2026-05-06

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Germ Cell and Embryonal, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡